Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Am J Gastroenterol

Retrieve available abstracts of 302 articles:
HTML format



Single Articles


    March 2024
  1. ALLEGRETTI JR, Axelrad J, Dalal RS, Kelly CR, et al
    Outcomes after Fecal Microbiota Transplantation in combination with Bezlotoxumab for Inflammatory Bowel Disease and Recurrent C . difficile Infection.
    Am J Gastroenterol. 2024 Mar 19. doi: 10.14309/ajg.0000000000002770.
    PubMed     Abstract available


  2. KHAN N, Sundararajan R, Patel M, Trivedi C, et al
    Effectiveness Of Tofacitinib In Ulcerative Colitis Patients: A Nationwide Veterans Administration Cohort study.
    Am J Gastroenterol. 2024 Mar 14. doi: 10.14309/ajg.0000000000002761.
    PubMed     Abstract available


  3. DALAL RS, Kallumkal G, Cabral HJ, Barnes EL, et al
    One-Year Comparative Effectiveness of Upadacitinib Versus Tofacitinib For Ulcerative Colitis: A Multicenter Cohort Study.
    Am J Gastroenterol. 2024 Mar 12. doi: 10.14309/ajg.0000000000002746.
    PubMed     Abstract available


  4. EBACH DR, Jester TW, Galanko JA, Firestine AM, et al
    High Body Mass Index and Response to Anti-TNF Therapy in Pediatric Crohn Disease.
    Am J Gastroenterol. 2024 Mar 6. doi: 10.14309/ajg.0000000000002741.
    PubMed     Abstract available


    February 2024
  5. ANDERSON KL, Anand R, Feuerstein JD
    Insurance Companies' Poor Adherence to Guidelines for Moderate to Severe Ulcerative Colitis/Crohn's Disease Management.
    Am J Gastroenterol. 2024 Feb 29. doi: 10.14309/ajg.0000000000002720.
    PubMed     Abstract available


  6. FRIEDMAN S, Nielsen J, Qvist N, Knudsen T, et al
    Does surgery prior to pregnancy in women with inflammatory bowel disease increase the risk of adverse maternal and fetal outcomes? A Danish national cohort study.
    Am J Gastroenterol. 2024 Feb 20. doi: 10.14309/ajg.0000000000002732.
    PubMed     Abstract available


  7. HERFARTH H
    Dysplasia Detection in Inflammatory Bowel Disease: An Updated Meta-Analysis With Effect.
    Am J Gastroenterol. 2024 Feb 16. doi: 10.14309/ajg.0000000000002658.
    PubMed    


  8. SMITH RA, Desai A, Barnes EL, Hayney M, et al
    Patients with Inflammatory Bowel Disease are at Increased Risk for Hospitalization Due to Respiratory Syncytial Virus.
    Am J Gastroenterol. 2024 Feb 6. doi: 10.14309/ajg.0000000000002682.
    PubMed     Abstract available


  9. SUN J, Yao J, Olen O, Halfvarson J, et al
    Long-term risk of myocarditis in patients with inflammatory bowel disease: a nationwide cohort study in Sweden.
    Am J Gastroenterol. 2024 Feb 5. doi: 10.14309/ajg.0000000000002701.
    PubMed     Abstract available


  10. COHEN-MEKELBURG S, Valicevic A, Lin L, Saini SD, et al
    Inflammatory Bowel Disease Hospitalizations are Similar for Patients Receiving Tele-Visit Delivered Outpatient Care and Those Receiving Traditional In-Person Care.
    Am J Gastroenterol. 2024 Feb 5. doi: 10.14309/ajg.0000000000002703.
    PubMed     Abstract available


  11. VAGIANOS K, Dolovich C, Witges K, Graff LA, et al
    Ultra-processed food, disease activity and inflammation in Ulcerative Colitis: The Manitoba Living with IBD Study.
    Am J Gastroenterol. 2024 Feb 2. doi: 10.14309/ajg.0000000000002667.
    PubMed     Abstract available


  12. DRAGONI G, Innocenti T, Amiot A, Castiglione F, et al
    Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with tofacitinib vs biologics: a multicenter observational study.
    Am J Gastroenterol. 2024 Feb 2. doi: 10.14309/ajg.0000000000002676.
    PubMed     Abstract available


  13. ANDREW B, Trinh S, Zhou A, Vasudevan A, et al
    Anal Cancer in Crohn's Disease: The Need to Optimize Treatment and Improve Surveillance.
    Am J Gastroenterol. 2024;119:390-391.
    PubMed    


  14. COWARD S, Benchimol EI, Bernstein CN, Avina-Zubieta A, et al
    Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian nationwide analysis.
    Am J Gastroenterol. 2024 Feb 1. doi: 10.14309/ajg.0000000000002687.
    PubMed     Abstract available


  15. FAYE AS, Axelrad JE, Sun J, Halfvarson J, et al
    Atherosclerosis as a Risk Factor of Inflammatory Bowel Disease: A Population-Based Case-Control Study.
    Am J Gastroenterol. 2024;119:313-322.
    PubMed     Abstract available


  16. DALAL RS, Norgard BM, Zegers FD, Kjeldsen J, et al
    Older Adult-Onset of Inflammatory Bowel Diseases Is Associated With Higher Utilization of Analgesics: A Nationwide Cohort Study.
    Am J Gastroenterol. 2024;119:323-330.
    PubMed     Abstract available


  17. FEAGINS LA, Gold S, Steinlauf AF
    Overview of Biosimilars in Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2024;119:229-232.
    PubMed    


    January 2024
  18. CHETWOOD JD, Ko Y, Pudipeddi A, Kariyawasam V, et al
    Biological agents in the treatment of Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC3) study.
    Am J Gastroenterol. 2024 Jan 26. doi: 10.14309/ajg.0000000000002679.
    PubMed     Abstract available


  19. BERINSTEIN JA, Karl T, Patel A, Dolinger M, et al
    Effectiveness of Upadacitinib for Patients with Acute Severe Ulcerative Colitis: A Multi-Center Experience.
    Am J Gastroenterol. 2024 Jan 26. doi: 10.14309/ajg.0000000000002674.
    PubMed     Abstract available


  20. TANDON P, Huang V, Feig DS, Saskin R, et al
    Recent Immigrants with Inflammatory Bowel Disease Have Significant Health-Care Utilization from Preconception to Postpartum: A Population Cohort Study.
    Am J Gastroenterol. 2024 Jan 23. doi: 10.14309/ajg.0000000000002668.
    PubMed     Abstract available


  21. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
    Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naive Crohn's Disease.
    Am J Gastroenterol. 2024 Jan 18. doi: 10.14309/ajg.0000000000002654.
    PubMed     Abstract available


  22. MA T, Han D, Sun M
    Acute Pancreatitis After Microscopic Colitis: Is It due to Drugs or Disease?
    Am J Gastroenterol. 2024;119:215-216.
    PubMed    


  23. KIWAN W
    Continuing Medical Education Questions: January 2024.
    Am J Gastroenterol. 2024;119:29.
    PubMed     Abstract available


    December 2023
  24. DOLINGER MT, Aronskyy I, Kellar A, Gao M, et al
    Determining the accuracy of intestinal ultrasound scores as a pre-screening tool in Crohn's disease clinical trials.
    Am J Gastroenterol. 2023 Dec 22. doi: 10.14309/ajg.0000000000002632.
    PubMed     Abstract available


  25. SINGH A, Goyal MK, Midha V, Mahajan R, et al
    Tofacitinib in acute severe ulcerative colitis (TACOS): A randomized controlled trial: Tofacitinib in ASUC.
    Am J Gastroenterol. 2023 Dec 22. doi: 10.14309/ajg.0000000000002635.
    PubMed     Abstract available


  26. AFIF W, Arasaradnam RP, Abreu MT, Danese S, et al
    Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-term Maintenance Study.
    Am J Gastroenterol. 2023 Dec 14. doi: 10.14309/ajg.0000000000002621.
    PubMed     Abstract available


  27. WEI L, Patil SA, Cross RK, Taubenslag KJ, et al
    Cystoid macular edema after initiation of ozanimod for ulcerative colitis.
    Am J Gastroenterol. 2023 Dec 12. doi: 10.14309/ajg.0000000000002622.
    PubMed    


  28. BOUSVAROS A
    Collaborative Registries for Pediatric Crohn's Disease: A Leap Forward or More of the Same?
    Am J Gastroenterol. 2023 Dec 5. doi: 10.14309/ajg.0000000000002590.
    PubMed    


  29. WEISS A, Barnes EL, Bewtra M
    A Practical Guide to the Use of Upadacitinib in Ulcerative Colitis and Crohn's Disease.
    Am J Gastroenterol. 2023 Dec 4. doi: 10.14309/ajg.0000000000002598.
    PubMed    


  30. BOURGONJE AR, Mian P
    Identifying Phenotypic Determinants of Infliximab Target Concentrations in Inflammatory Bowel Disease: Toward Personalized Evidence-Based Dosing Regimens.
    Am J Gastroenterol. 2023;118:2308-2309.
    PubMed    


  31. DULANEY DT
    Continuing Medical Education Questions: December 2023.
    Am J Gastroenterol. 2023;118:2122.
    PubMed     Abstract available


    November 2023
  32. KAYAL M, Deepak P, Beniwal-Patel P, Raffals L, et al
    Changes in Therapy Are Not Associated with Increased Remission in Patients with Crohn's Disease of the Pouch.
    Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002599.
    PubMed     Abstract available


  33. ANDREW B, Vasudevan A, Srinivasan A
    The Role of Intestinal Ultrasound During Pregnancy in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023;118:2096-2097.
    PubMed    


  34. BARNES EL, Desai A, Kochhar GS
    The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study.
    Am J Gastroenterol. 2023;118:1989-1996.
    PubMed     Abstract available


  35. SANTIAGO P, Barnes EL, Raffals LE
    Classification and Management of Disorders of the J Pouch.
    Am J Gastroenterol. 2023;118:1931-1939.
    PubMed     Abstract available


  36. SACHDEVA K, Agarwal S, Kumar P, Mathew D, et al
    Revised Algorithmic Approach to Differentiate Between Nonspecific and Specific Etiologies of Chronic Terminal Ileitis.
    Am J Gastroenterol. 2023;118:2052-2060.
    PubMed     Abstract available


  37. YARUR AJ, Abreu MT, Deepak P, Beniwal-Patel P, et al
    Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission.
    Am J Gastroenterol. 2023;118:2005-2013.
    PubMed     Abstract available


  38. MOHAN BP, Fatima N, Khan SR, Kassab L, et al
    Early Remission With Induction Therapy Predicts Long-Term Remission in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2023;118:2084-2087.
    PubMed    


  39. KOCHAR B, Mao EJ, Shah SA
    Optimal Dysplasia Detection and Management in IBD: Now and in the Future.
    Am J Gastroenterol. 2023;118:1905-1908.
    PubMed    


  40. DUNLEAVY KA, Cross RK, Raffals LE
    Causes, Diagnostic Testing, and Treatment of Residual Symptoms in Patients With IBD With Quiescent Disease.
    Am J Gastroenterol. 2023;118:1909-1914.
    PubMed    


    October 2023
  41. GENERE JR, Ballard DH, Deepak P
    Three-Dimensional Modeling to Guide Interventional Endoscopy in Fibrostenotic Crohn's Disease.
    Am J Gastroenterol. 2023 Oct 13. doi: 10.14309/ajg.0000000000002558.
    PubMed    


  42. PHAM JT, Ghusn W, Acosta A, Loftus EV Jr, et al
    Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 Oct 9. doi: 10.14309/ajg.0000000000002490.
    PubMed     Abstract available


  43. DEBRUYN JC, Huynh HQ, Griffiths AM, Jacobson K, et al
    ADALIMUMAB VERSUS INFLIXIMAB IN LUMINAL PEDIATRIC CROHN'S DISEASE: COMPARABLE OUTCOMES IN A PROSPECTIVE MULTICENTER COHORT STUDY.
    Am J Gastroenterol. 2023 Oct 3. doi: 10.14309/ajg.0000000000002552.
    PubMed     Abstract available


  44. SHUJA A
    Continuing Medical Education Questions: October 2023.
    Am J Gastroenterol. 2023;118:1742.
    PubMed     Abstract available


  45. COELHO-PRABHU N, Lewis JD
    Update on Endoscopic Dysplasia Surveillance in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023;118:1748-1755.
    PubMed     Abstract available


    September 2023
  46. ALSOUD D, Ho J, Sabino J, Ferrante M, et al
    Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis.
    Am J Gastroenterol. 2023 Sep 27. doi: 10.14309/ajg.0000000000002518.
    PubMed     Abstract available


  47. BAK MTJ, Huinink STB, Erler NS, Bodelier AGL, et al
    Prognostic value of the modified Rutgeerts' score for long-term outcomes after primary ileocecal resection in Crohn's disease.
    Am J Gastroenterol. 2023 Sep 22. doi: 10.14309/ajg.0000000000002509.
    PubMed     Abstract available


  48. CAIRNS CA, Cross RK, Khambaty M, Bafford AC, et al
    Monitoring Patients with Inflammatory Bowel Disease at High Risk of Anal Cancer.
    Am J Gastroenterol. 2023 Sep 18. doi: 10.14309/ajg.0000000000002503.
    PubMed     Abstract available


  49. SANTIAGO P, Coelho-Prabhu N, Lennon R, Rui S, et al
    Baseline Clinical Factors are Associated with Risk of Complications in Crohn's Disease: Appraisal of the AGA Clinical Care Pathway.
    Am J Gastroenterol. 2023 Sep 15. doi: 10.14309/ajg.0000000000002498.
    PubMed     Abstract available


  50. WILKERSON RC
    Continuing Medical Education Questions: September 2023.
    Am J Gastroenterol. 2023;118:1543.
    PubMed     Abstract available


  51. KAHN-BOESEL O, Cautha S, Ufere NN, Ananthakrishnan AN, et al
    A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States.
    Am J Gastroenterol. 2023;118:1545-1553.
    PubMed     Abstract available


    August 2023
  52. CHANG S, Murphy M, Malter L
    A Review of Available Medical Therapies to Treat Moderate to Severe Inflammatory Bowel Disease in 2023.
    Am J Gastroenterol. 2023 Aug 24. doi: 10.14309/ajg.0000000000002485.
    PubMed     Abstract available


  53. LEVARTOVSKY A, Ben-Horin S, Kopylov U, Klang E, et al
    Towards AI-Augmented Clinical Decision Making: An Examination of ChatGPT's Utility in Acute Ulcerative Colitis Presentations.
    Am J Gastroenterol. 2023 Aug 23. doi: 10.14309/ajg.0000000000002483.
    PubMed     Abstract available


  54. YANG Y, Ludvigsson JF, Olen O, Sjolander A, et al
    Absolute and relative risks of kidney and urological complications in patients with inflammatory bowel disease.
    Am J Gastroenterol. 2023 Aug 10. doi: 10.14309/ajg.0000000000002473.
    PubMed     Abstract available


  55. RAMPERTAB SD
    Continuing Medical Education Questions: August 2023.
    Am J Gastroenterol. 2023;118:1321.
    PubMed     Abstract available


  56. BOPARAI ES, Lee JK, Zhu S, Shirazi A, et al
    The Contemporary Probability of Occult Colorectal Cancer in Patients With Colitis-Related Dysplasia Undergoing Colectomy.
    Am J Gastroenterol. 2023;118:1453-1456.
    PubMed     Abstract available


    July 2023
  57. DUBINSKY M, Bleakman AP, Panaccione R, Hibi T, et al
    Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions.
    Am J Gastroenterol. 2023 Jul 12. doi: 10.14309/ajg.0000000000002404.
    PubMed     Abstract available


  58. FERNANDEZ C, Gajic Z, Esen E, Remzi F, et al
    Preoperative Risk Factors for Adverse Events in Adults Undergoing Bowel Resection for Inflammatory Bowel Disease: 15-Year Assessment of ACS-NSQIP.
    Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002395.
    PubMed     Abstract available


  59. BONFILS L, Sandri AK, Poulsen GJ, Agrawal M, et al
    Medication-wide study: Exploring medication use ten years prior to a diagnosis of inflammatory bowel disease.
    Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002399.
    PubMed     Abstract available


  60. BACHOUR SP, Khan MZ, Shah RS, Joseph A, et al
    Anastomotic configuration and temporary diverting ileostomy do not increase risk for anastomotic stricture in postoperative Crohn's disease.
    Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002393.
    PubMed     Abstract available


  61. VUYYURU SK, Archer M, Nguyen TM, Beaton M, et al
    Long washout periods between biologics for inflammatory bowel disease clinical trials are unnecessary: A Canadian retrospective cohort study.
    Am J Gastroenterol. 2023 Jul 6. doi: 10.14309/ajg.0000000000002398.
    PubMed     Abstract available


  62. BALI AS, Hashash JG, Picco MF, Kinnucan JA, et al
    Electronic Health Record Burden Among Gastroenterology Providers Associated With Subspecialty and Training.
    Am J Gastroenterol. 2023;118:1282-1284.
    PubMed     Abstract available


    June 2023
  63. HU FH, Chen HL
    Low Risk of Lymphoma in Pediatric Patients Treated for Inflammatory Bowel Disease: Need More Evidence.
    Am J Gastroenterol. 2023;118:1101-1102.
    PubMed    


  64. DULANEY DT
    Continuing Medical Education Questions: June 2023.
    Am J Gastroenterol. 2023;118:935.
    PubMed     Abstract available


  65. DULANEY DT
    Continuing Medical Education Questions: June 2023.
    Am J Gastroenterol. 2023;118:935.
    PubMed     Abstract available


    May 2023
  66. MARKOVINOVIC A, Quan J, Herauf M, Hracs L, et al
    Adverse Events & Serological Responses Following SARS-CoV-2 Vaccination in Individuals with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 May 22. doi: 10.14309/ajg.0000000000002337.
    PubMed     Abstract available


  67. BARNES EL, Zhang X, Long MD, Herfarth HH, et al
    Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative Colitis.
    Am J Gastroenterol. 2023 May 22. doi: 10.14309/ajg.0000000000002331.
    PubMed     Abstract available


  68. PARIAN AM, Obi M, Fleshner P, Schwartz DA, et al
    Management of Perianal Crohn's Disease - AJG.
    Am J Gastroenterol. 2023 May 19. doi: 10.14309/ajg.0000000000002326.
    PubMed     Abstract available


  69. LEY D, Leroyer A, Dupont C, Sarter H, et al
    New therapeutic strategies are associated with a significant decrease in colectomy rate in pediatric ulcerative colitis.
    Am J Gastroenterol. 2023 May 4. doi: 10.14309/ajg.0000000000002316.
    PubMed     Abstract available


  70. GOLDOWSKY A, Billings W, Kickel A, Charabaty A, et al
    @MondayNightIBD and the Expanding Gastroenterology Twitterverse: A Study on Continuing Medical Education on #GITwitter.
    Am J Gastroenterol. 2023;118:855-860.
    PubMed     Abstract available


    April 2023
  71. MORTREUX P, Leroyer A, Dupont C, Ley D, et al
    Natural history of anal ulcerations in pediatric-onset Crohn's disease: long-term follow-up of a population-based study.
    Am J Gastroenterol. 2023 Apr 25. doi: 10.14309/ajg.0000000000002301.
    PubMed     Abstract available


  72. COHEN-MEKELBURG S, Van T, Berinstein JA, Yu X, et al
    Characteristics of Facilities with Early and Rapid Ustekinumab Adoption for Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 Apr 25. doi: 10.14309/ajg.0000000000002304.
    PubMed     Abstract available


  73. YANG JY, Lund JL, Funk MJ, Hudgens MG, et al
    Utilization of Treat-to-Target Monitoring Colonoscopy after Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD).
    Am J Gastroenterol. 2023 Apr 13. doi: 10.14309/ajg.0000000000002294.
    PubMed     Abstract available


  74. MARCHEGIANI F, Laurent A, de'Angelis N
    Abdominal mass in a patient with autoimmune hepatitis, ulcerative colitis and BRCA family history - not always what you expect.
    Am J Gastroenterol. 2023 Apr 11. doi: 10.14309/ajg.0000000000002284.
    PubMed    


    March 2023
  75. AHUJA D, Murad MH, Ma C, Jairath V, et al
    Comparative Speed of Early Symptomatic Remission with Advanced Therapies for Moderate-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Am J Gastroenterol. 2023 Mar 29. doi: 10.14309/ajg.0000000000002263.
    PubMed     Abstract available


  76. OGINO T, Mizushima T, Fujii M, Sekido Y, et al
    Crohn's disease-associated anorectal cancer has a poor prognosis with high local recurrence: a subanalysis of the Nationwide Japanese Study.
    Am J Gastroenterol. 2023 Mar 28. doi: 10.14309/ajg.0000000000002269.
    PubMed     Abstract available


  77. ZORZI F, Rubin DT, Cleveland NK, Monteleone G, et al
    Ultrasonographic Transmural healing in Crohn's disease.
    Am J Gastroenterol. 2023 Mar 28. doi: 10.14309/ajg.0000000000002265.
    PubMed     Abstract available


  78. FINE LS, Zhu S, Shirazi A, Lee JK, et al
    Increased Risk of Hospitalization, Surgery and Venous Thromboembolism Among Patients with Inflammatory Bowel Disease and Malnutrition in a Large, Community-Based Healthcare System.
    Am J Gastroenterol. 2023 Mar 9. doi: 10.14309/ajg.0000000000002241.
    PubMed     Abstract available


    February 2023
  79. CARD TR, Nakafero G, Grainge MJ, Mallen CD, et al
    Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.
    Am J Gastroenterol. 2023 Feb 22. doi: 10.14309/ajg.0000000000002205.
    PubMed     Abstract available


  80. VUYYURU SK, Rieder F, Solitano V, Nguyen TM, et al
    Patients with Crohn's disease and permanent ileostomy are universally excluded from clinical trials: A systematic review.
    Am J Gastroenterol. 2023 Feb 8. doi: 10.14309/ajg.0000000000002215.
    PubMed     Abstract available


  81. MURTHY SK, Benchimol EI
    Low Risk of Lymphoma in Children With IBD Is Reassuring to Clinicians and Families.
    Am J Gastroenterol. 2023;118:261-262.
    PubMed    


  82. OTLEY A, Grover Z, Moayyedi P
    Working to Answer the Effectiveness of Nutrition in IBD: Still a Ways to Go.
    Am J Gastroenterol. 2023;118:256-258.
    PubMed     Abstract available


  83. CHO JJ, Pak K, Austin RP, Padilla L, et al
    Endometriosis of the Appendix, Cecum, and Ileum Masquerading as Suspected Crohn's Disease.
    Am J Gastroenterol. 2023;118:197.
    PubMed    


  84. OLLECH JE, Yanai H, Avni-Biron I, Snir Y, et al
    Fecal Calprotectin and Quality of Life Questionnaires Are Responsive to Change in Pouch Disease Activity After Antibiotic Therapy: Results From a Prospective Clinical Trial.
    Am J Gastroenterol. 2023;118:367-370.
    PubMed     Abstract available


  85. JOHNSON AM, Barsky M, Ahmed W, Zullow S, et al
    The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
    Am J Gastroenterol. 2023;118:317-328.
    PubMed     Abstract available


    January 2023
  86. KAWASAKI K, Kawatoko S, Yamamoto H, Torisu T, et al
    Sessile Serrated Lesion of the Rectum in Ulcerative Colitis Observed by Image-Enhanced Endoscopy.
    Am J Gastroenterol. 2023 Jan 30. doi: 10.14309/ajg.0000000000002175.
    PubMed    


  87. REN T, Yu Y, Wang H, Li F, et al
    Maternal Inflammatory Bowel Disease During Pregnancy and Infectious Disease in Offspring Younger Than 5 Years: A Population-Based Cohort Study.
    Am J Gastroenterol. 2023 Jan 26. doi: 10.14309/ajg.0000000000002179.
    PubMed     Abstract available


  88. SUN Y, Yuan S, Chen X, Sun J, et al
    The Contribution of Genetic Risk and Lifestyle Factors in the Development of Adult-Onset Inflammatory Bowel Disease: A Prospective Cohort Study.
    Am J Gastroenterol. 2023 Jan 26. doi: 10.14309/ajg.0000000000002180.
    PubMed     Abstract available


  89. LE COSQUER G, Celerier B, Laharie D
    A Rare Cause of Colonic Obstruction in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 Jan 23. doi: 10.14309/ajg.0000000000002116.
    PubMed    


  90. ANDERSON J, Frost S, Keyashian K, Modiano N, et al
    Pentosan Polysulfate-Associated Dysplasia in Patients With Inflammatory Bowel Disease: A Case Series.
    Am J Gastroenterol. 2023 Jan 23. doi: 10.14309/ajg.0000000000002137.
    PubMed     Abstract available


  91. LARSEN L, Sandri AK, Fallingborg J, Jacobsen BA, et al
    Has the incidence of inflammatory bowel disease peaked? Evidence from the population-based NorDIBD Cohort 1978-2020.
    Am J Gastroenterol. 2023 Jan 13. doi: 10.14309/ajg.0000000000002187.
    PubMed     Abstract available


  92. SEISHIMA R, Okabayashi K, Ikeuchi H, Uchino M, et al
    Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
    Am J Gastroenterol. 2023 Jan 9. doi: 10.14309/ajg.0000000000002149.
    PubMed     Abstract available


  93. HEUTHORST L, Harbech H, Snijder HJ, Mookhoek A, et al
    Increased Proportion of Colorectal Cancer in Patients With Ulcerative Colitis Undergoing Surgery in the Netherlands.
    Am J Gastroenterol. 2023 Jan 6. doi: 10.14309/ajg.0000000000002099.
    PubMed     Abstract available


  94. CHEIFETZ AS, Vande Casteele N, Wang Z, Dubinsky MC, et al
    Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial.
    Am J Gastroenterol. 2023 Jan 5. doi: 10.14309/ajg.0000000000002096.
    PubMed     Abstract available


  95. TSE CS, Singh S, Valasek MA, Neill J, et al
    Prevalence and Correlations of Gastrointestinal Symptoms With Endoscopic and Histologic Mucosal Healing in Crohn's Disease.
    Am J Gastroenterol. 2023 Jan 5. doi: 10.14309/ajg.0000000000002122.
    PubMed     Abstract available


  96. NARULA N, Wong ECL, Marshall JK, Jairath V, et al
    Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
    Am J Gastroenterol. 2023;118:121-128.
    PubMed     Abstract available


    December 2022
  97. AXELRAD JE, Cross RK
    Surveillance for colorectal neoplasia in inflammatory bowel disease: When to stop.
    Am J Gastroenterol. 2022 Dec 29. doi: 10.14309/ajg.0000000000002168.
    PubMed    


  98. TAKENAKA K, Kitazume Y, Kawamoto A, Fujii T, et al
    Serum Leucine-Rich alpha2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease.
    Am J Gastroenterol. 2022 Dec 27. doi: 10.14309/ajg.0000000000002127.
    PubMed     Abstract available


  99. UKASHI O, Kopylov U, Ungar B, Haj-Natour O, et al
    Patency capsule: A novel independent predictor for long-term outcomes among patients with quiescent Crohn's disease.
    Am J Gastroenterol. 2022 Dec 23. doi: 10.14309/ajg.0000000000002118.
    PubMed     Abstract available


  100. ACOSTA MB, Fernandez-Clotet A, Mesonero F, Garcia-Alonso FJ, et al
    Long-term outcomes of biological therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU.
    Am J Gastroenterol. 2022 Dec 14. doi: 10.14309/ajg.0000000000002152.
    PubMed     Abstract available


  101. CHAPARRO M, Acosta D, Rodriguez C, Mesonero F, et al
    Real-world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness and safety.
    Am J Gastroenterol. 2022 Dec 14. doi: 10.14309/ajg.0000000000002145.
    PubMed     Abstract available


  102. MA C, Panaccione R, Xiao Y, Khandelwal Y, et al
    REMIT-UC: Real World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis.
    Am J Gastroenterol. 2022 Dec 8. doi: 10.14309/ajg.0000000000002129.
    PubMed     Abstract available


  103. BERENBLUM TOBI C
    Principles for Assessing Quality of Life in Patients With Crohn's Disease.
    Am J Gastroenterol. 2022;117:1952-1953.
    PubMed     Abstract available


  104. SHAFI MA
    Continuing Medical Education Questions: December 2022.
    Am J Gastroenterol. 2022;117:1910.
    PubMed     Abstract available


    November 2022
  105. KAPPELMAN MD, Adimadhyam S, Hou L, Wolfe AE, et al
    Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease.
    Am J Gastroenterol. 2022 Nov 23. doi: 10.14309/ajg.0000000000002068.
    PubMed     Abstract available


  106. KHAN N, Mahmud N
    COVID-19 Vaccine Effectiveness Against the Omicron Variant in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Nov 23. doi: 10.14309/ajg.0000000000002071.
    PubMed     Abstract available


  107. VARMA A, Weinstein J, Seabury J, Rosero S, et al
    Patient-Reported Impact of Symptoms in Crohn's Disease.
    Am J Gastroenterol. 2022 Nov 15. doi: 10.14309/ajg.0000000000001954.
    PubMed     Abstract available


  108. BIRCH RJ, Burr N, Subramanian V, Tiernan JP, et al
    Inflammatory Bowel Disease-Associated Colorectal Cancer Epidemiology and Outcomes: An English Population-Based Study.
    Am J Gastroenterol. 2022;117:1858-1870.
    PubMed     Abstract available


  109. DUNLEAVY K, Fogwe D, Forde G, Ho M, et al
    A Rare Complication: Postoperative Pyoderma Gangrenosum in Segmental Colitis Associated With Diverticulosis.
    Am J Gastroenterol. 2022;117:1734.
    PubMed    


  110. CHENG D, Kochar B, Cai T, Ritchie CS, et al
    Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:1845-1850.
    PubMed     Abstract available


    October 2022
  111. BERNSTEIN CN, Fisk JD, Walld R, Bolton JM, et al
    Use of Benzodiazepines and Z-Drugs in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Oct 27. pii: 00000434-990000000-00474.
    PubMed     Abstract available


  112. FAIRBRASS KM, Guthrie EA, Black CJ, Selinger CP, et al
    Characteristics and Impact of Anxiety and Depression Trajectories in Inflammatory Bowel Disease.: Anxiety and Depression Trajectories in IBD.
    Am J Gastroenterol. 2022 Oct 12. pii: 00000434-990000000-00552.
    PubMed     Abstract available


  113. EGBERG MD, Zhang X, Smitherman AB, Kappelman MD, et al
    LOW RISK OF LYMPHOMA IN PEDIATRIC PATIENTS TREATED FOR INFLAMMATORY BOWEL DISEASE.
    Am J Gastroenterol. 2022 Oct 10. pii: 00000434-990000000-00543.
    PubMed     Abstract available


  114. DONG J, Ladonne M, Feuerstein JD
    Medicare Patients Face High Out-of-Pocket Costs for Specialty Inflammatory Bowel Disease Medications.
    Am J Gastroenterol. 2022 Oct 10. pii: 00000434-990000000-00549.
    PubMed     Abstract available


  115. INAMDAR S
    Continuing Medical Education Questions: October 2022.
    Am J Gastroenterol. 2022;117:1564.
    PubMed     Abstract available


  116. SHMIDT E, Dubinsky MC
    Inflammatory Bowel Disease and Pregnancy.
    Am J Gastroenterol. 2022;117.
    PubMed    


  117. GU P, Luo J, Kim J, Paul P, et al
    Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Am J Gastroenterol. 2022;117:1639-1647.
    PubMed     Abstract available


    September 2022
  118. KASTL A, Weaver KN, Zhang X, Strople JA, et al
    Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00507.
    PubMed     Abstract available


  119. GUPTA A, Kizza JF, Ananthakrishnan AN
    Histologic activity in an endoscopically normal appearing pouch predicts future risk of pouchitis in patients with ulcerative colitis.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00511.
    PubMed     Abstract available


  120. DULANEY DT
    Continuing Medical Education Questions: September 2022.
    Am J Gastroenterol. 2022;117:1407.
    PubMed     Abstract available


  121. BOSCHETTI G, Nachury M, Laharie D, Roblin X, et al
    Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID.
    Am J Gastroenterol. 2022;117:1482-1490.
    PubMed     Abstract available


    August 2022
  122. DANESE S, Ferrante M, Feagan BG, Peyrin-Biroulet L, et al
    Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
    Am J Gastroenterol. 2022 Aug 23. pii: 00000434-990000000-00486.
    PubMed     Abstract available


  123. COHEN-MEKELBURG S, Van T, Wallace B, Berinstein J, et al
    The association between non-steroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: a true association or residual bias?
    Am J Gastroenterol. 2022 Aug 12. pii: 00000434-990000000-00457.
    PubMed     Abstract available


  124. AGRAWAL M, Allin KH, Iversen AT, Mehandru S, et al
    Early life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study.
    Am J Gastroenterol. 2022 Aug 12. pii: 00000434-990000000-00466.
    PubMed     Abstract available


  125. VAN DEEN WK, Simpson M, Dupuy TP, Khalil C, et al
    Social Media for the Dissemination of Educational Videos About Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:1320-1323.
    PubMed     Abstract available


  126. ONALI S, Pugliese D, Caprioli FA, Orlando A, et al
    An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
    Am J Gastroenterol. 2022;117:1279-1287.
    PubMed     Abstract available


    July 2022
  127. BESSISSOW T, Kron CM, Marcus V, Lemieux C, et al
    Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis.
    Am J Gastroenterol. 2022 Jul 21. pii: 00000434-990000000-00439.
    PubMed     Abstract available


  128. LO B, Liu Z, Bendtsen F, Igel C, et al
    High accuracy in classifying endoscopic severity in ulcerative colitis using convolutional neural network.
    Am J Gastroenterol. 2022 Jul 15. pii: 00000434-990000000-00434.
    PubMed     Abstract available


  129. ISAACS K, Kane S
    Doctor, What Is the Best Crohn's Therapy?
    Am J Gastroenterol. 2022;117:1041-1043.
    PubMed     Abstract available


  130. JAIN A, Bricker J, Kappelman MD, Dotson JL, et al
    Overweight and Obese Status Is Not Associated With Disease Activity for Children and Adolescents With Newly Diagnosed Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022;117:1146-1153.
    PubMed     Abstract available


  131. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
    Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
    Am J Gastroenterol. 2022;117:1106-1117.
    PubMed     Abstract available


    June 2022
  132. ALMARIO CV, van Deen WK, Chen M, Gale R, et al
    Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results from a Randomized Trial.
    Am J Gastroenterol. 2022 Jun 10. pii: 00000434-990000000-00406.
    PubMed     Abstract available


    May 2022
  133. MARILD K, Soderling J, Lebwohl B, Green PH, et al
    ASSOCIATION OF CELIAC DISEASE AND INFLAMMATORY BOWEL DISEASE: A NATIONWIDE REGISTER-BASED COHORT STUDY.
    Am J Gastroenterol. 2022 May 25. pii: 00000434-990000000-00380.
    PubMed     Abstract available


    April 2022
  134. KAPLAN HC, Opipari-Arrigan L, Yang J, Schmid CH, et al
    Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease (PRODUCE): A Series of N-of-1 Diet Trials.
    Am J Gastroenterol. 2022 Apr 20. pii: 00000434-990000000-00348.
    PubMed     Abstract available


  135. LUTZ M, Hayney MS, Caldera F
    We should not forget about patients with inflammatory bowel disease who received a COVID-19 viral vector vaccine.
    Am J Gastroenterol. 2022 Apr 15. pii: 00000434-990000000-00337.
    PubMed    


  136. DULAI PS, Rai V, Raffals LE, Lukin D, et al
    Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel.
    Am J Gastroenterol. 2022 Apr 13. pii: 00000434-990000000-00329.
    PubMed    


  137. SASSINE S, Djani L, Cambron-Asselin C, Savoie M, et al
    Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease: A Retrospective Cohort Study.
    Am J Gastroenterol. 2022;117:637-646.
    PubMed     Abstract available


    March 2022
  138. ROLAK S, Caldera F
    The current knowns and unknowns of COVID-19 vaccine induced immunity in patients with inflammatory bowel disease.
    Am J Gastroenterol. 2022 Mar 15. pii: 00000434-990000000-00282.
    PubMed    


  139. WINTER RW, Friedman S, Nielsen J, Kjeldsen J, et al
    Infliximab Is Not Associated With a General Long-Term Weight Gain in Patients With Inflammatory Bowel Disease: A Nationwide Study.
    Am J Gastroenterol. 2022 Mar 14. pii: 00000434-990000000-00278.
    PubMed     Abstract available


  140. KAPPELMAN MD, Weaver KN, Zhang X, Dai X, et al
    Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:462-469.
    PubMed     Abstract available


    February 2022
  141. SNINSKY JA, Barnes EL, Zhang X, Long MD, et al
    Urgency and its association with quality of life and clinical outcomes in ulcerative colitis patients.
    Am J Gastroenterol. 2022 Feb 15. pii: 00000434-990000000-00253.
    PubMed     Abstract available


    January 2022
  142. TSIPOTIS E, Frey S, Connolly C, Werbel WA, et al
    Antibody Response Three Months after Two-Dose SARS-CoV-2 mRNA Vaccination in patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00231.
    PubMed     Abstract available


  143. HAMADA K, Mankawa N, Yamamoto S
    May-Thurner syndrome in a patient with ulcerative colitis complicated by coronavirus disease 2019.
    Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00233.
    PubMed    


  144. GARRIDO I, Lopes S, Andrade P, Real AC, et al
    Immune Response Induced by SARS-CoV-2 Vaccines in Patients With Inflammatory Bowel Disease Under Biologic Therapy.
    Am J Gastroenterol. 2022 Jan 24. pii: 00000434-990000000-00217.
    PubMed    


    December 2021
  145. MOLLY S, Margaret M, Erin F
    P076 The Role of Dual Biologic Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  146. JARED S, Edward B, Xian Z, Millie L, et al
    P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
    Am J Gastroenterol. 2021;116.
    PubMed    


  147. RAHUL D, Jennifer M, Hannah G, Jessica A, et al
    P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  148. BENJAMIN S, Kristine P, Kevin T, James M, et al
    P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.
    Am J Gastroenterol. 2021;116.
    PubMed    


  149. JOSE RL, Jesus LG, Tomas CE, Korely TF, et al
    P063 Prevalence in the Use of Complementary/Alternative Medicine in Patients With Inflammatory Bowel Disease from Centro Medico Nacional 20 de Noviembre.
    Am J Gastroenterol. 2021;116.
    PubMed    


  150. KORELY TF, Jesus LG, Tomas CE, Rebeca PC, et al
    P061 Impact of Inflammatory Bowel Disease on sleep quality in a Mexican population attended in a referral center.
    Am J Gastroenterol. 2021;116.
    PubMed    


  151. VIVIANA PI, Jaiber G, Cristian F, Diego J, et al
    P060 Screening Criteria of Inflammatory Bowel Disease: Application in Colombian Patients With Spondyloarthritis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  152. JULTON TC, Lauren S, Mouhammed S, Adil M, et al
    P058 Impact of Inflammatory Bowel Disease Treatment and Risk of Covid-19 Infection after Full Immunization: A Nationwide Analysis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  153. CARLOS PA, Tomas CE, Jesus LG, Korely TF, et al
    P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20.
    Am J Gastroenterol. 2021;116.
    PubMed    


  154. VIVIANA PI, Juan FO, Pablo G, Consuelo RS, et al
    P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
    Am J Gastroenterol. 2021;116.
    PubMed    


  155. SANG TC, Sarah A, Yousef E, Joshua T, et al
    P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares.
    Am J Gastroenterol. 2021;116.
    PubMed    


  156. MIKAELL F, Ligia S, Adriana A, Roberto KJ, et al
    P052 National Registration of Patients With Inflammatory Bowel Disease in Brazil on Behalf of GEDIIB.
    Am J Gastroenterol. 2021;116.
    PubMed    


  157. MARTA F, Tiago LC, Vitor MS, Catia A, et al
    P051 Identifying High-Risk Patients With Acute Severe Ulcerative Colitis: Is the ACE Index Useful?
    Am J Gastroenterol. 2021;116.
    PubMed    


  158. VIVIANA PI, Katherin C, Julio A, Maria B, et al
    P050 Oral Inflammatory Changes Associated With Inflammatory Bowel Disease in Spondyloarthritis Associated With Early Endoscopic Findings.
    Am J Gastroenterol. 2021;116.
    PubMed    


  159. DANIEL S, Marina L, Ana Carolina O, Rodrigo B, et al
    P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  160. MARINA L, Daniel S, Ana Carolina O, Rodrigo B, et al
    P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
    Am J Gastroenterol. 2021;116.
    PubMed    


  161. QIAN C, Myrlene S, Nurgul B, Lilla DS, et al
    P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  162. MILLIE L, Raymond C, Jonathan C, Marc P, et al
    P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  163. JEAN-FREDERIC C, Geert D, Peter I, AnnKatrin P, et al
    P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Am J Gastroenterol. 2021;116.
    PubMed    


  164. DAVID H, Millie L, Douglas W, Stephen H, et al
    P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  165. BRUCE S, Marc P, Michael S, AnnKatrin P, et al
    P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  166. DAVID R, Remo P, Alison PB, Cem K, et al
    P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
    Am J Gastroenterol. 2021;116.
    PubMed    


  167. APAAR D, Khushboo G, Jayesh R, Shesh R, et al
    P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics.
    Am J Gastroenterol. 2021;116.
    PubMed    


  168. ADAM S, Nicole L, Heba I, Harini N, et al
    P026 Inflammatory Bowel Disease (IBD) Related Outcomes in Patients Diagnosed With COVID-19.
    Am J Gastroenterol. 2021;116.
    PubMed    


  169. SIGRID Y, Scott S, Shannon C
    P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  170. KEVIN C, Sandra K, Noll R
    P023 Parental Distress in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  171. VARUN J, Brian B, Esteban F
    P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  172. VITOR MS, Tiago LC, Marta F, Tiago CG, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    PubMed    


  173. IANA G, Randall J, Marc P
    P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  174. MARIYA Z, Oleg K, Karina N
    P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  175. RICHARD WY
    P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay.
    Am J Gastroenterol. 2021;116.
    PubMed    


  176. HARTMAN B, Diana H, Casey C
    P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
    Am J Gastroenterol. 2021;116.
    PubMed    


  177. OLEG K, Sergey K, Anna K, Albina L, et al
    P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  178. OLEG K, Anna K, Albina L, Anait B, et al
    P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
    Am J Gastroenterol. 2021;116.
    PubMed    


  179. HUI C, Tian F, Lintao D, Xuejie C, et al
    P003 Meat Consumption and All-Cause Mortality in 5763 Inflammatory Bowel Disease Patients: A Prospective Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  180. STONE M, Morrison M, Forster E
    P076 The Role of Dual Biologic Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  181. SNINSKY J, Barnes E, Zhang X, Long M, et al
    P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  182. DALAL R, Mitri J, Goodrick H, Allegretti J, et al
    P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  183. SAHN B, Pascuma K, Tracey K, Markowitz J, et al
    P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  184. ROMERO LJ, Gomez JL, Espinosa TC, Trujillo de la Fuente K, et al
    P063 Prevalence in the Use of Complementary/Alternative Medicine in Patients With Inflammatory Bowel Disease from Centro Medico Nacional 20 de Noviembre.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  185. TRUJILLO DE LA FUENTE K, Lopez Gomez J, Cortes Espinosa T, Perez-Cabeza de Vaca R, et al
    P061 Impact of Inflammatory Bowel Disease on sleep quality in a Mexican population attended in a referral center.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  186. PARRA IZQUIERDO V, Gutierrez J, Florez C, Jaimes D, et al
    P060 Screening Criteria of Inflammatory Bowel Disease: Application in Colombian Patients With Spondyloarthritis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  187. PAREDES AMENABAR C, Cortes Espinosa T, Lopez Gomez J, Trujillo de la Fuente K, et al
    P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  188. PARRA IZQUIERDO V, Frias-Ordonez J, Galindo P, Romero-Sanchez C, et al
    P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  189. TSE CS, Andrea S, Elfanagely Y, Tanzer J, et al
    P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  190. FARIA M, Sassaki L, Andrade A, Kaiser Junior R, et al
    P052 National Registration of Patients With Inflammatory Bowel Disease in Brazil on Behalf of GEDIIB.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  191. FREITAS M, Capela TL, Macedo Silva V, Arieira C, et al
    P051 Identifying High-Risk Patients With Acute Severe Ulcerative Colitis: Is the ACE Index Useful?
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  192. PARRA IZQUIERDO V, Chumacero K, Alvarado J, Buenahora M, et al
    P050 Oral Inflammatory Changes Associated With Inflammatory Bowel Disease in Spondyloarthritis Associated With Early Endoscopic Findings.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  193. SHINTAKU D, Lopes M, de Oliveira AC, Beraldo R, et al
    P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  194. LOPES M, Shintaku D, de Oliveira AC, Beraldo R, et al
    P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  195. CAI Q, Sanon M, Batyrbekova N, Di Scala L, et al
    P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  196. LONG M, Cross R, Calkwood J, Pondel M, et al
    P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  197. COLOMBEL JF, D'Haens G, Irving P, Petersen A, et al
    P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  198. HUDESMAN D, Long M, Wolf D, Hanauer S, et al
    P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  199. SANDS B, Pondel M, Silver M, Petersen A, et al
    P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  200. RUBIN D, Panaccione R, Potts Bleakman A, Kayhan C, et al
    P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  201. DADLANI A, Gala K, Rai J, Rai S, et al
    P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  202. YOUNG S, Smukalla S, Chang S
    P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  203. CESA K, Kim S, Robert N
    P023 Parental Distress in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  204. JAIN V, Behm B, Figueroa E
    P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  205. MACEDO SILVA V, Lima Capela T, Freitas M, Curdia Goncalves T, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  206. GUEORGUIEVA I, Jacobs R, Piper M
    P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  207. ZVYAGLOVA M, Knyazev O, Noscova K
    P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  208. WANG YR
    P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  209. BRUNT H, Hamer D, Chapman C
    P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  210. KNYAZEV O, Khomeriki S, Kagramanova A, Lishchinskaya A, et al
    P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  211. KNYAZEV O, Kagramanova A, Lishchinskaya A, Babayan A, et al
    P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  212. CHEN H, Fu T, Dan L, Chen X, et al
    P003 Meat Consumption and All-Cause Mortality in 5763 Inflammatory Bowel Disease Patients: A Prospective Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  213. DAI C, Jiang M, Huang YH
    The Association Between Serum Infliximab Concentrations and Clinical Outcomes in Fistulizing Crohn's Disease.
    Am J Gastroenterol. 2021;116:2481-2482.
    PubMed    


    November 2021
  214. MELMED GY, Oliver B, Hou JK, Lum D, et al
    Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Nov 19. pii: 00000434-990000000-00153.
    PubMed     Abstract available


  215. CALDERA F, Knutson KL, Saha S, Wald A, et al
    Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls.
    Am J Gastroenterol. 2021 Nov 18. pii: 00000434-990000000-00148.
    PubMed     Abstract available


  216. BRUNT H, Chapman JC
    The Inflammatory Bowel Disease-Focused Primary Care Provider: An Addition to the IBD Specialty Medical Home.
    Am J Gastroenterol. 2021 Nov 17. pii: 00000434-990000000-00144.
    PubMed    


  217. NGUYEN NH, Martinez I, Atreja A, Sitapati AM, et al
    Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2021 Nov 9. pii: 00000434-990000000-00141.
    PubMed     Abstract available


  218. ALMARIO CV, Kogan L, van Deen WK, Scott FI, et al
    Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Nov 3. pii: 00000434-990000000-00133.
    PubMed     Abstract available


  219. CHO JM, Loftus EV Jr, Bruining DH, Chedid VG, et al
    Vulvar Crohn's Disease: Clinical Features and Outcomes.
    Am J Gastroenterol. 2021;116:2296-2299.
    PubMed     Abstract available


    October 2021
  220. LAUBE R, Tran Y, Paramsothy S, Leong RW, et al
    Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2021 Oct 25. pii: 00000434-990000000-00131.
    PubMed     Abstract available


  221. THAKUR K, Barrett TA
    Social Determinants of Health in Inflammatory Bowel Diseases: Barriers and Opportunities.
    Am J Gastroenterol. 2021;116:2146.
    PubMed    


  222. ASHHAB AA, Lee M, Melmed GY
    Extensive Upper Gastrointestinal Fistulization in Crohn's Disease, an Uncommon Cause for a Common Presentation.
    Am J Gastroenterol. 2021;116:1978.
    PubMed    


    September 2021
  223. BATTAT R, Long MD
    Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data.
    Am J Gastroenterol. 2021 Sep 13. pii: 00000434-990000000-00100.
    PubMed     Abstract available


    August 2021
  224. SANGHA M, Roitman I, Sultan K, Swaminath A, et al
    SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares.
    Am J Gastroenterol. 2021 Aug 18. pii: 00000434-990000000-00081.
    PubMed    


  225. CHEIFETZ AS, Abreu MT, Afif W, Cross RK, et al
    A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Aug 13. pii: 00000434-990000000-00067.
    PubMed     Abstract available


  226. RICCIUTO A, Carman N, Benchimol EI, Siddiqui I, et al
    Prospective Evaluation of Endoscopic and Histologic Indices in Pediatric Ulcerative Colitis Using Centralized Review.
    Am J Gastroenterol. 2021 Aug 13. pii: 00000434-990000000-00066.
    PubMed     Abstract available


  227. DULAI PS, Jairath V, Narula N, Wong E, et al
    A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease.
    Am J Gastroenterol. 2021;116:1709-1719.
    PubMed     Abstract available


    July 2021
  228. HARRISON N, Humes R, Singla M
    Skip, Stop, Switch, and Spare: Steroid Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Jul 19. pii: 00000434-990000000-00049.
    PubMed    


  229. SCHUMANN M, Sonnenberg E, Siegmund B, Meier K, et al
    A 39-Year-Old Man With Crohn's Disease and a Unclear Rash on His Left Cheek.
    Am J Gastroenterol. 2021;116:1374.
    PubMed    


    June 2021
  230. ABDALLA MI, Levesque BG
    Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement.
    Am J Gastroenterol. 2021;116:1187-1188.
    PubMed     Abstract available


  231. TARGOWNIK LE, Bernstein CN, Benchimol EI, Kaplan GG, et al
    Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis.
    Am J Gastroenterol. 2021;116:1284-1293.
    PubMed     Abstract available


    May 2021
  232. DE GIORGI V, Trane L, Silvestri F, Venturi F, et al
    Pyodermatitis-Pyostomatitis Vegetans in Active Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 May 31. pii: 00000434-900000000-98762.
    PubMed    


  233. BOTWIN GJ, Li D, Figueiredo J, Cheng S, et al
    Adverse Events Following SARS-CoV-2 mRNA Vaccination: Among Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 May 25. pii: 00000434-900000000-98766.
    PubMed     Abstract available


  234. TEICH N, Stallmach A, Bruns T
    Greenspace in Childhood: A New Avenue to Prevent Inflammatory Bowel Disease?
    Am J Gastroenterol. 2021 May 7. pii: 00000434-900000000-98784.
    PubMed    


  235. TANG J, Huang Z, Guo H, Ding N, et al
    Online Video Clinic Satisfies the Medical Requirements of Patients with IBD During the COVID-19 Outbreak.
    Am J Gastroenterol. 2021;116:1087.
    PubMed    


  236. PAPAMICHAEL K, Vande Casteele N, Jeyarajah J, Jairath V, et al
    Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
    Am J Gastroenterol. 2021;116:1007-1014.
    PubMed     Abstract available


    April 2021
  237. KHAN N, Patel D, Xie D, Pernes T, et al
    Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.
    Am J Gastroenterol. 2021;116:808-810.
    PubMed     Abstract available


  238. KHAN N, Patel D, Trivedi C, Kavani H, et al
    Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
    Am J Gastroenterol. 2021;116:741-747.
    PubMed     Abstract available


  239. SONNENBERG A
    Do Forgotten Symptoms Need Treatment?
    Am J Gastroenterol. 2021;116:841-842.
    PubMed    


  240. HA C
    The Age-Old Conundrum With Thiopurines: Are the Accumulating Risks Greater Than Benefits?
    Am J Gastroenterol. 2021;116:671-672.
    PubMed     Abstract available


    March 2021
  241. BERNSTEIN CN, Nugent Z, Singh H
    Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study.
    Am J Gastroenterol. 2021 Mar 24. pii: 00000434-900000000-98845.
    PubMed     Abstract available


  242. SLATER NR, Loomes DE
    Endoscopic Vacuum-Assisted Wound Closure of a Rectal Perforation in the Setting of Active Ulcerative Colitis.
    Am J Gastroenterol. 2021 Mar 2. pii: 00000434-900000000-98819.
    PubMed    


    January 2021
  243. COELHO-PRABHU N, Kane S
    Does Size Really Matter?
    Am J Gastroenterol. 2021;116:84-85.
    PubMed     Abstract available


  244. HAMMOUDI N, Allez M
    Response to Hanzel.
    Am J Gastroenterol. 2021;116:218.
    PubMed    


  245. HANZEL J
    A Novel Endoscopic Score for Postoperative Recurrence of Crohn's Disease: More Information Needed.
    Am J Gastroenterol. 2021;116:217-218.
    PubMed    


  246. RIVIERE P, D'Haens G, Peyrin-Biroulet L, Baert F, et al
    Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
    Am J Gastroenterol. 2021;116:134-141.
    PubMed     Abstract available


    December 2020
  247. LACY BE, Pimentel M, Brenner DM, Chey WD, et al
    ACG Clinical Guideline: Management of Irritable Bowel Syndrome.
    Am J Gastroenterol. 2020 Dec 14. doi: 10.14309/ajg.0000000000001036.
    PubMed     Abstract available


  248. KORELITZ BI, Sachar DB, Schneider J
    Full Potential of 6-Mercaptopurine in IBD May Remain Untapped.
    Am J Gastroenterol. 2020;115:2109-2110.
    PubMed    


  249. FERNANDA F, Mirella O, Danielle F, Pedro G, et al
    P074 Prevalence and Associated Factors With Non-Adherence to Maintenance Therapy for Ulcerative Colitis in Deep Remission.
    Am J Gastroenterol. 2020;115.
    PubMed    


  250. PRADEEP KR, Deloshaan S, Dheeraj S, Hadi M, et al
    P070 Outcomes of Acute Severe Ulcerative Colitis in Older Adults.
    Am J Gastroenterol. 2020;115.
    PubMed    


  251. DELOSHAAN S, Pradeep KR, Dheeraj S, Hadi M, et al
    P069 Admission Steroid Use, Serum Albumin and Endoscopic Severity Predict Intravenous Steroid Failure in Patients With Acute Severe Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  252. JAQUELINE B, Juliana C, Dos Santos B, Caroline D, et al
    P068 Therapeutic Aspects in Pediatric Inflammatory Bowel Disease - A Multi-Centric Study From Brazil.
    Am J Gastroenterol. 2020;115.
    PubMed    


  253. FLAVIA P, Cyrla Z, de Souza H, Jessica M, et al
    P066 Hospitalization and Surgery Rates in Patients With Inflammatory Bowel Disease in Brazil: A Time-Trend Analysis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  254. JENNIFER MO, Megan L, Jean A
    P065 Inflammatory Bowel Disease or Bowel Endometriosis? Two Cases of Large Bowel Obstruction.
    Am J Gastroenterol. 2020;115.
    PubMed    


  255. JAQUELINE B, Juliana C, Dos Santos Beatriz, Caroline D, et al
    P064 Clinical Aspects of Pediatric Inflammatory Bowel Disease - A Multicentric Study From Brazil.
    Am J Gastroenterol. 2020;115.
    PubMed    


  256. FABIANA B, Cesar A, Marcio C, Carolina M, et al
    P061 Prophylaxis of Hepatitis B Reactivation and Inflammatory Bowel Disease: A case report.
    Am J Gastroenterol. 2020;115.
    PubMed    


  257. SVETLANA L, Morris G, Vasiliki S
    P056 Power Calculations in Randomised Controlled Trials of Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020;115.
    PubMed    


  258. WALAA M, Hisham W, Walid H, Fadi F, et al
    P049 Should the Gallbladder be Empirically Removed at Time of Intestinal Resection in Inflammatory Bowel Disease Patients?
    Am J Gastroenterol. 2020;115.
    PubMed    


  259. ERIC J
    P047 Awareness and Impact of Recent AGA Guideline Changes for Moderate to Severe Ulcerative Colitis Patients.
    Am J Gastroenterol. 2020;115.
    PubMed    


  260. ERIC J
    P046 Though Biosimilar Infliximab Prescribing in Inflammatory Bowel Disease Has Increased, Branded Infliximab Continues to Be Prescribed More Often.
    Am J Gastroenterol. 2020;115.
    PubMed    


  261. CASEY C, Jenny G, Michelle B, Joe L, et al
    P042 The CONCERT Initiative: Impact of Inflammatory Bowel Disease Care Referral Pathway.
    Am J Gastroenterol. 2020;115.
    PubMed    


  262. SARA L, Millie L, Uma M
    P040 Indications for Cesarean Section in Pregnant Women with Inflammatory Bowel Disease: Results from the PIANO Registry.
    Am J Gastroenterol. 2020;115.
    PubMed    


  263. SARA H, David H, Joe Z, Ryan H, et al
    P038 Factors Associated with Impaired Patient-Reported Outcomes and Work Productivity Among Patients with Ulcerative Colitis in Remission.
    Am J Gastroenterol. 2020;115.
    PubMed    


  264. DAVID P, Caterina O, Christopher A, Gregory AC, et al
    P037 Efficacy and Safety of 1-L NER1006 Bowel Preparation in Patients with Inflammatory Bowel Disease: Analysis of 2 Phase 3 Studies.
    Am J Gastroenterol. 2020;115.
    PubMed    


  265. CLARA U, Amanda T, Debora T, Giovana C, et al
    P036 Clinical and Psychological Factors Associated with Impaired Body Image in Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020;115.
    PubMed    


  266. KAUSTAV S, Austin T, Roman G, Allison M, et al
    P033 Demographic Factors Associated with Successful Telehealth Visits in Inflammatory Bowel Disease Patients.
    Am J Gastroenterol. 2020;115.
    PubMed    


  267. WILLIAM S, Brian F, Stephen H, Severine V, et al
    P031 Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension.
    Am J Gastroenterol. 2020;115.
    PubMed    


  268. SILVIO D, Brian F, Stephen H, Igor J, et al
    P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  269. EDWARD B, Harris A, Joe Z, Antoine S, et al
    P027 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD.
    Am J Gastroenterol. 2020;115.
    PubMed    


  270. SHINTARO A, Jacob O, Cindy T, Victoria R, et al
    P026 Assessment of Contributing Factors for Fistula Development in Patients with Inflammatory Bowel Disease Treated by Proctocolectomy with Ileal Pouch-Anal Anastomosis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  271. WILLIAM S, Geert D, Doug W, Stephen H, et al
    P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  272. GALIYA B, Alisa R, Maria L
    P024 Medical Decision Support System in the Diagnosis of Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  273. MICHAEL C, Puza S, Benjamin C, Leonardo S, et al
    P021 Characteristics of Patients Treated with Tofacitinib for Ulcerative Colitis in the Real World: Findings from a Large US Claims Database.
    Am J Gastroenterol. 2020;115.
    PubMed    


  274. SUBRATA G, Geert D, Vipul J, Florian R, et al
    P012 Ozanimod Reduced Fecal Calprotectin Levels in Patients with Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  275. ROGERIO P, Julio C, Liliana C, Erika B, et al
    P008 Long-Term Effectiveness and Safety of Ustekinumab for The Treatment of Crohn s Disease: A Brazilian Multicentre Real-world Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  276. OLEG K, Albina L, Anatoliy K, Anna K, et al
    P005 Overcoming Secondary Loss of Response to Infliximab in Patients With Ulcerative Colitis With the Use of Mesenchymal Stromal Cells.
    Am J Gastroenterol. 2020;115.
    PubMed    


  277. OLEG K, Anna K, Albina L, Tatyana S, et al
    P002 Frequency and Causes of Prolongation of the Induction Course of Tofacitinib in Patients with Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  278. ERNESTO R, Rachel H, Meera L, Pablo P, et al
    P001 North-South Gradient in the Incidence of Pediatric Inflammatory Bowel Disease Along the Atlantic Coast.
    Am J Gastroenterol. 2020;115.
    PubMed    


    November 2020
  279. KHAN N, Patel D, Trivedi C, Kavani H, et al
    Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
    Am J Gastroenterol. 2020 Nov 26. doi: 10.14309/ajg.0000000000001058.
    PubMed     Abstract available


  280. ZAVER HB, Ghoz H, Azar A, Alexander LF, et al
    Inferior Mesenteric Arteriovenous Malformation Masquerading as Ulcerative Colitis.
    Am J Gastroenterol. 2020 Nov 10. doi: 10.14309/ajg.0000000000000917.
    PubMed    


  281. CHAPARRO M, Gordillo J, Domenech E, Esteve M, et al
    Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
    Am J Gastroenterol. 2020;115:1802-1811.
    PubMed     Abstract available


  282. BANTY A, Melmed GY
    Improving Hepatitis B Virus Vaccination Responses in Inflammatory Bowel Disease: Does Greater Dose and Greater Frequency Lead to Greater Protection?
    Am J Gastroenterol. 2020;115:1797-1798.
    PubMed     Abstract available


  283. LITTLE DHW, Tabatabavakili S, Shaffer SR, Nguyen GC, et al
    Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2020;115:1768-1774.
    PubMed     Abstract available


  284. WINDSOR JW, Underwood FE, Brenner E, Colombel JF, et al
    Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry.
    Am J Gastroenterol. 2020;115:1923-1924.
    PubMed    


  285. CHAPUIS-BIRON C, Kirchgesner J, Pariente B, Bouhnik Y, et al
    Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
    Am J Gastroenterol. 2020;115:1812-1820.
    PubMed     Abstract available


    October 2020
  286. BUCHNER AM, Schneider Y, Lichtenstein GR
    Biosimilars in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020 Oct 27. doi: 10.14309/ajg.0000000000000844.
    PubMed     Abstract available


  287. GUBATAN J, Nielsen OH, Levitte S, Juhl CB, et al
    Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2020 Oct 23. doi: 10.14309/ajg.0000000000000910.
    PubMed     Abstract available


  288. KHAN N, Patel D, Xie D, Pernes T, et al
    Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.
    Am J Gastroenterol. 2020 Oct 19. doi: 10.14309/ajg.0000000000001012.
    PubMed     Abstract available


  289. ELTEN M, Benchimol EI, Fell DB, Kuenzig ME, et al
    Residential Greenspace in Childhood Reduces Risk of Pediatric Inflammatory Bowel Disease: A Population-Based Cohort Study.
    Am J Gastroenterol. 2020 Oct 8. doi: 10.14309/ajg.0000000000000990.
    PubMed     Abstract available


  290. FIORINO G, Gilardi D, Radice S, Furfaro F, et al
    Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures.
    Am J Gastroenterol. 2020;115:1719-1721.
    PubMed     Abstract available


  291. MANSOOR E, Khoudari G, Abou Saleh M, Elfadawy N, et al
    The Many Faces of COVID-19: Atypical Presentation of COVID-19 in a Patient With Crohn's Disease With Acute Diarrhea Leading to Severe Hypovolemic Hyponatremia-A Case Report.
    Am J Gastroenterol. 2020;115:1730-1731.
    PubMed    


  292. GIESE-KIM N, Wu M, Dehghan M, Sceats LA, et al
    Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:1698-1706.
    PubMed     Abstract available


    September 2020
  293. CHAPARRO M, Gordillo J, Domenech E, Esteve M, et al
    Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
    Am J Gastroenterol. 2020 Sep 30. doi: 10.14309/ajg.0000000000000926.
    PubMed     Abstract available


  294. BANTY A, Melmed GY
    Improving Hepatitis B Virus Vaccination Responses in Inflammatory Bowel Disease: Does Greater Dose and Greater Frequency Lead to Greater Protection?
    Am J Gastroenterol. 2020 Sep 25. doi: 10.14309/ajg.0000000000000921.
    PubMed     Abstract available


  295. DALAL RS, Palchaudhuri S, Snider CK, Gitelman Y, et al
    A Multimodal Intervention Using Nonopioid Analgesics Is Associated With Reduced Intravenous Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:1474-1485.
    PubMed     Abstract available


  296. QUINN KP, Raffals LE
    An Update on the Medical Management of Inflammatory Pouch Complications.
    Am J Gastroenterol. 2020;115:1439-1450.
    PubMed     Abstract available


    August 2020
  297. NARULA N, Wong ECL, Aruljothy A, Dulai PS, et al
    Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.
    Am J Gastroenterol. 2020;115:1236-1245.
    PubMed     Abstract available


    July 2020
  298. HAMMOUDI N, Auzolle C, Tran Minh ML, Boschetti G, et al
    Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease.
    Am J Gastroenterol. 2020;115:1084-1093.
    PubMed     Abstract available


    June 2020
  299. ROZICH JJ, Holmer A, Singh S
    Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:832-840.
    PubMed     Abstract available


    May 2020
  300. BEWTRA M, Lichtenstein GR
    Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy.
    Am J Gastroenterol. 2020;115:687-688.
    PubMed     Abstract available


  301. LEE MW, Pourmorady JS, Laine L
    Use of Fecal Occult Blood Testing as a Diagnostic Tool for Clinical Indications: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2020;115:662-670.
    PubMed     Abstract available


    March 2020
  302. SHAH A, Macdonald GA, Morrison M, Holtmann G, et al
    Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
    Am J Gastroenterol. 2020 Mar 25. doi: 10.14309/ajg.0000000000000604.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.